AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
2 United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
3 AstraZeneca agrees strategic transaction with Almirall in respiratory disease
4 MedImmune and Advaxis partner on immuno-oncology combination clinical trial
5 AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
6 AstraZeneca and Max Planck Institute announce research agreement
7 AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
8 Clarification regarding Pfizer statement
9 MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
10 AstraZeneca Board rejects Pfizer proposal
11 AstraZeneca and MRC enter strategic collaboration
12 MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
13 FDA Advisory Committee votes on investigational medicine metreleptin
14 AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex
15 AstraZeneca advances MedImmune's benralizumab to Phase III in severe asthma
16 AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
17 AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
18 AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
19 MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
20 AstraZeneca PLC second quarter and half year results 2013
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]